undamentalytics Newsletter
Sign in

Vistagen Therapeutics, Inc. cash flow statement

In fiscal 2026, Vistagen Therapeutics, Inc.'s operations generated −$66.4m of cash; it spent $0 on capital projects, leaving free cash flow of −$66.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Mar 20112012Mar 20122013Mar 20132016Mar 20162017Mar 20172018Mar 20182020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Cash from operations−1−4−3−5−7−9−16−12−45−50−26−42−66−62
Depreciation and amortisation00000000000000
Stock-based pay22141242332444
Capital spending———00000010000
Free cash flow———−5−8−9−16−12−45−50−26−42−66−62
Free cash flow after stock pay———−9−8−11−20−15−49−54−28−46−70−66
Shares issued—3101017313—093001

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KRRO vs VTGNCLGN vs VTGNUPB vs VTGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vistagen Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vistagen Therapeutics, Inc.